Investors in Indian pharmaceutical stock - hit by quality-related sanctions against drugmakers operating abroad and reduced pricing power in more profitable markets- have adopted a new mantra: patience and pickiness. Fund managers said they are becoming increasingly fastidious regarding India's $16 billion drugs sector, with a preference for shares in smaller firms such as Natco Pharma Ltd and Cadila Healthcare Ltd with less exposure to the overseas issues curbing growth at larger rivals. "I think sticking to smaller players and not having a lot of exposure to very large ...
Investors ride out big-pharma slump with small-cap drugmakers
Indian pharmaceutical stock hit by quality-related sanctions against drugmakers operating abroad